Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform.
- DOI
- 10.1016/j.ajhg.2026.03.018
- Published
- 2026 May 7
- Container
- American journal of human genetics
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ajhg.2026.03.018,
title = {Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform.},
author = {Feierman ER and Whittaker MN and Quigley A and Brooks DL and McVeigh P and Nan AX and Hsu A and Said H and Soliman OY and Giovenco R and Davidson BL and Alameh MG and Liu DR and Wang X and Musunuru K and Ahrens-Nicklas RC},
year = {2026},
journal = {American journal of human genetics},
doi = {10.1016/j.ajhg.2026.03.018},
url = {https://doi.org/10.1016/j.ajhg.2026.03.018}
}RIS
TY - JOUR TI - Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform. AU - Feierman ER AU - Whittaker MN AU - Quigley A AU - Brooks DL AU - McVeigh P AU - Nan AX AU - Hsu A AU - Said H AU - Soliman OY AU - Giovenco R AU - Davidson BL AU - Alameh MG AU - Liu DR AU - Wang X AU - Musunuru K AU - Ahrens-Nicklas RC PY - 2026 JO - American journal of human genetics DO - 10.1016/j.ajhg.2026.03.018 UR - https://doi.org/10.1016/j.ajhg.2026.03.018 ER -
APA
ER, F., MN, W., A, Q., DL, B., P, M., AX, N., A, H., H, S., OY, S., R, G., BL, D., MG, A., DR, L., X, W., K, M., & RC, A. (2026). Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform.. American journal of human genetics. https://doi.org/10.1016/j.ajhg.2026.03.018
Source records
- pubmed · retrieved 2026-09-27T08:13:33.726Z